Literature DB >> 27757522

Post-dilatation after implantation of bioresorbable everolimus- and novolimus-eluting scaffolds: an observational optical coherence tomography study of acute mechanical effects.

Florian Blachutzik1, Niklas Boeder2, Jens Wiebe3, Alessio Mattesini4, Oliver Dörr2, Astrid Most2, Timm Bauer2, Jens Röther5, Monique Tröbs5, Christian Schlundt5, Stephan Achenbach5, Christian W Hamm2, Holger M Nef2.   

Abstract

OBJECTIVES: The objective was to investigate the acute mechanical effects of post-dilatation on bioresorbable scaffolds (BRS) as determined by optical coherence tomography (OCT).
BACKGROUND: Post-dilatation with high-pressure balloons is regarded as a key component of BRS implantation for treatment of coronary artery stenoses. However, the impact of post-dilatation on BRS in vivo has not been thoroughly investigated.
METHODS: OCT was performed after the implantation procedure of 51 everolimus-eluting or novolimus-eluting polylactic acid-based BRS with (n = 27) or without non-compliant balloon post-dilatation (n = 24). The number of malapposed struts, strut fractures, edge dissections, residual in-scaffold area stenosis, and incomplete scaffold apposition area was analyzed over the complete length of each BRS with a spacing of 1 mm.
RESULTS: OCT revealed a significantly lower incomplete scaffold apposition area if post-dilatation was performed (0.16 ± 0.49 mm2 with post-dilatation vs. 2.65 ± 2.78 mm2 without post-dilatation, p < 0.001), as well as a significantly lower absolute number of malapposed struts (1 ± 2 with post-dilatation vs. 13 ± 13 without post-dilatation, p < 0.001). No significant differences regarding residual in-scaffold area stenosis, strut fracture, edge dissection, symmetry index, or eccentricity index were observed in patients with vs. without post-dilatation.
CONCLUSION: Post-dilatation of BRS with non-compliant balloons significantly reduces the number of malapposed struts and incomplete scaffold apposition area without inducing higher rates of edge dissection or strut fracture.

Entities:  

Keywords:  Bioresorbable vascular scaffolds; Coronary artery disease; Optical coherence tomography; Percutaneous coronary intervention (PCI)

Mesh:

Substances:

Year:  2016        PMID: 27757522     DOI: 10.1007/s00392-016-1048-z

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  28 in total

1.  Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study.

Authors:  Josep Gomez-Lara; Roberto Diletti; Salvatore Brugaletta; Yoshinobu Onuma; Vasim Farooq; Leif Thuesen; Dougal McClean; Jacques Koolen; John A Ormiston; Stefan Windecker; Robert Whitbourn; Dariusz Dudek; Cécile Dorange; Susan Veldhof; Richard Rapoza; Evelyn Regar; Hector M Garcia-Garcia; Patrick W Serruys
Journal:  EuroIntervention       Date:  2012-06-20       Impact factor: 6.534

2.  Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities.

Authors:  Cihan Simsek; Antonios Karanasos; Michael Magro; Hector M Garcia-Garcia; Yoshinobu Onuma; Evelyn Regar; Eric Boersma; Patrick W Serruys; Robert J van Geuns
Journal:  EuroIntervention       Date:  2016-01-22       Impact factor: 6.534

3.  Absorb vs. DESolve: an optical coherence tomography comparison of acute mechanical performances.

Authors:  Alessio Mattesini; Niklas Boeder; Serafina Valente; Katja Löblich; Oliver Dörr; Gioel G Secco; Nicolas Foin; Gianluca Caiazzo; Matteo Ghione; Gian Franco Gensini; Italo Porto; Carlo Di Mario; Holger Nef
Journal:  EuroIntervention       Date:  2016-08-05       Impact factor: 6.534

4.  Combined use of optical coherence tomography and intravascular ultrasound imaging in patients undergoing coronary interventions for stent thrombosis.

Authors:  Fernando Alfonso; Jaime Dutary; Manuel Paulo; Nieves Gonzalo; Maria J Pérez-Vizcayno; Pilar Jiménez-Quevedo; Javier Escaned; Camino Bañuelos; Rosana Hernández; Carlos Macaya
Journal:  Heart       Date:  2012-08       Impact factor: 5.994

5.  Predictors and outcomes of stent thrombosis: an intravascular ultrasound registry.

Authors:  Neal G Uren; S P Schwarzacher; J A Metz; D P Lee; Y Honda; A C Yeung; P J Fitzgerald; P G Yock
Journal:  Eur Heart J       Date:  2002-01       Impact factor: 29.983

6.  Impact of post-dilation on the acute and one-year clinical outcomes of a large cohort of patients treated solely with the Absorb Bioresorbable Vascular Scaffold.

Authors:  José De Ribamar Costa; Alexandre Abizaid; Antonio L Bartorelli; Robert Whitbourn; Robert Jan van Geuns; Bernard Chevalier; Marcos Perin; Ashok Seth; Roberto Botelho; Patrick W Serruys
Journal:  EuroIntervention       Date:  2015-06       Impact factor: 6.534

7.  Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the sirius trial.

Authors:  Shinjo Sonoda; Yoshihiro Morino; Junya Ako; Mitsuyasu Terashima; Ali H M Hassan; Heidi N Bonneau; Martin B Leon; Jeffrey W Moses; Paul G Yock; Yasuhiro Honda; Richard E Kuntz; Peter J Fitzgerald
Journal:  J Am Coll Cardiol       Date:  2004-06-02       Impact factor: 24.094

8.  The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial.

Authors:  Pannipa Suwannasom; Yohei Sotomi; Yuki Ishibashi; Rafael Cavalcante; Felipe N Albuquerque; Carlos Macaya; John A Ormiston; Jonathan Hill; Irene M Lang; Mohaned Egred; Jean Fajadet; Maciej Lesiak; Jan G Tijssen; Joanna J Wykrzykowska; Robbert J de Winter; Bernard Chevalier; Patrick W Serruys; Yoshinobu Onuma
Journal:  JACC Cardiovasc Interv       Date:  2016-06-01       Impact factor: 11.195

9.  Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users : A position statement on the use of bioresorbable vascular scaffolds in the Netherlands.

Authors:  Bert Everaert; Cordula Felix; Jacques Koolen; Peter den Heijer; Jose Henriques; Joanna Wykrzykowska; Rene van der Schaaf; Bart de Smet; Sjoerd Hofma; Roberto Diletti; Nicolas Van Mieghem; Evelyn Regar; Peter Smits; Robert-Jan M van Geuns
Journal:  Neth Heart J       Date:  2015-03       Impact factor: 2.380

10.  Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience.

Authors:  Antonios Karanasos; Nicolas Van Mieghem; Nienke van Ditzhuijzen; Cordula Felix; Joost Daemen; Anouchska Autar; Yoshinobu Onuma; Mie Kurata; Roberto Diletti; Marco Valgimigli; Floris Kauer; Heleen van Beusekom; Peter de Jaegere; Felix Zijlstra; Robert-Jan van Geuns; Evelyn Regar
Journal:  Circ Cardiovasc Interv       Date:  2015-05       Impact factor: 6.546

View more
  3 in total

1.  Predictors for target lesion microcalcifications in patients with stable coronary artery disease: an optical coherence tomography study.

Authors:  Sebastian Reith; Andrea Milzi; Rosalia Dettori; Nikolaus Marx; Mathias Burgmaier
Journal:  Clin Res Cardiol       Date:  2018-04-13       Impact factor: 5.460

2.  Comparison between treatment of "established" versus complex "off-label" coronary lesions with Absorb® bioresorbable scaffold implantation: results from the GABI-R® registry.

Authors:  Aydin Huseynov; Stefan Baumann; Holger Nef; Thomas Riemer; Steffen Schneider; Thomas Pfannenbecker; Stephan Achenbach; Julinda Mehilli; Thomas Münzel; Tommaso Gori; Jochen Wöhrle; Ralf Zahn; Johannes Kastner; Axel Schmermund; Gert Richardt; Christian W Hamm; Ibrahim Akin
Journal:  Clin Res Cardiol       Date:  2019-06-29       Impact factor: 5.460

3.  Dissections after bioresorbable vascular scaffold implantation in the POLAR ACS Registry.

Authors:  Wojciech Zasada; Artur Dziewierz; Lukasz Partyka; Michal Wegiel; Beata Bobrowska; Rafal Depukat; Tomasz Rakowski; Dariusz Dudek; Stanislaw Bartus; Lukasz Rzeszutko
Journal:  Postepy Kardiol Interwencyjnej       Date:  2022-08-19       Impact factor: 1.065

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.